» Articles » PMID: 36623243

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in , , , , and

Abstract

Purpose: To estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in , , , , and .

Methods: The study population included 15,104 prospectively followed women within the CARRIERS study treated with ipsilateral surgery for invasive breast cancer. The risk of CBC was estimated for PV carriers in each gene compared with women without PVs in a multivariate proportional hazard regression analysis accounting for the competing risk of death and adjusting for patient and tumor characteristics. The primary analyses focused on the overall cohort and on women from the general population. Secondary analyses examined associations by race/ethnicity, age at primary breast cancer diagnosis, menopausal status, and tumor estrogen receptor (ER) status.

Results: Germline , , and PV carriers with breast cancer were at significantly elevated risk (hazard ratio > 1.9) of CBC, whereas only the PV carriers with ER-negative breast cancer had elevated risks (hazard ratio, 2.9). By contrast, PV carriers did not have significantly increased CBC risks. African American PV carriers had similarly elevated risks of CBC as non-Hispanic White PV carriers. Among premenopausal women, the 10-year cumulative incidence of CBC was estimated to be 33% for , 27% for , and 13% for PV carriers with breast cancer and 35% for PV carriers with ER-negative breast cancer. The 10-year cumulative incidence of CBC among postmenopausal PV carriers was 12% for , 9% for , and 4% for .

Conclusion: Women diagnosed with breast cancer and known to carry germline PVs in , , , or are at substantially increased risk of CBC and may benefit from enhanced surveillance and risk reduction strategies.

Citing Articles

Hodgkin lymphoma and Ewing sarcoma in pediatric patient carrying germline variant: a case report and literature review.

Czarny J, Galli D, Wziatek A, Pastorczak A, Szmyd B, Przybyszewski B Front Oncol. 2025; 15:1514697.

PMID: 40040726 PMC: 11876119. DOI: 10.3389/fonc.2025.1514697.


High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old.

van den Bruele A, Ren Y, Thomas S, Ntowe K, Rosenberger L, Menendez C Breast Cancer Res Treat. 2025; .

PMID: 40016543 DOI: 10.1007/s10549-025-07657-y.


Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue.

Liang X, Qin Y, Li P, Mo Y, Chen D Ther Adv Med Oncol. 2025; 17:17588359251321904.

PMID: 40012707 PMC: 11863263. DOI: 10.1177/17588359251321904.


CHEK2-related breast cancer: real-world challenges.

Weis L, Bychkovsky B, Hernandez A, Barroso-Sousa R, Sandoval R Fam Cancer. 2025; 24(1):23.

PMID: 39966186 DOI: 10.1007/s10689-025-00448-w.


Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies.

Manna E, Serrano D, Cazzaniga L, Mannucci S, Zanzottera C, Fava F Genes (Basel). 2025; 16(1).

PMID: 39858629 PMC: 11764557. DOI: 10.3390/genes16010082.


References
1.
Yadav S, Hart S, Hu C, Hillman D, Lee K, Gnanaolivu R . Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome. JCO Precis Oncol. 2020; 3. PMC: 7446380. DOI: 10.1200/PO.19.00067. View

2.
Palmer J, Polley E, Hu C, John E, Haiman C, Hart S . Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. J Natl Cancer Inst. 2020; 112(12):1213-1221. PMC: 7735769. DOI: 10.1093/jnci/djaa040. View

3.
Kuchenbaecker K, Hopper J, Barnes D, Phillips K, Mooij T, Roos-Blom M . Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017; 317(23):2402-2416. DOI: 10.1001/jama.2017.7112. View

4.
Gao X, Fisher S, Emami B . Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003; 56(4):1038-45. DOI: 10.1016/s0360-3016(03)00203-7. View

5.
de Bock G, Schutte M, Krol-Warmerdam E, Seynaeve C, Blom J, Brekelmans C . Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet. 2004; 41(10):731-5. PMC: 1735606. DOI: 10.1136/jmg.2004.019737. View